Merck to Sell Merial Stake to Sanofi for $4B

WHITEHOUSE STATION, N.J. ( TheStreet) -- Merck ( MRK) signed an agreement to sell its 50% interest in the Merial animal health joint venture for $4 billion in cash to its venture partner Sanofi-Aventis ( SNY).

Sanofi will own 100% of Merial once the transaction closes. The acquisition is expected to be accretive to Sanofi's adjusted net income from the first year.

The companies also signed a call option agreement, in which following the closing of the merger of Merck and Schering-Plough ( SGP), Sanofi could choose to combine the Intervet/Schering-Plough Animal Health business with Merial to form a joint venture that would be owned equally by Sanofi and the new Merck.

"These agreements should enable us to proceed expeditiously with the closing of our merger with Schering-Plough in the fourth quarter as planned, and also gain an outstanding animal health business through Intervet/Schering-Plough Animal Health," said Merck Chairman and CEO Richard Clark, in a statement Thursday.

More from Stocks

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker